# Mortimer D.A. Sackler **Mortimer David Alfons Sackler** (born 1971 or 1972; sources differ), often called Mortimer Sackler Jr., is the son of [[Mortimer Sackler]] by his second wife, Gertraud "Geri" Wimmer. He sat on the [[Purdue Pharma]] board through the [[OxyContin]] era and is one of the eight board-member heirs covered by the 2025 $7.4 billion settlement. The KB tracks him as the Sackler whose personal money trail is best documented in the court record. The shared family story lives on [[Sackler Family]]; this page carries what is specific to him. [[Theresa Sackler]], his father's third wife, is his stepmother, not his mother. [[Kathe Sackler]] and [[Ilene Sackler Lefcourt]] are half-sisters from his father's first marriage. ## Purdue and Mundipharma roles - The Massachusetts attorney general's amended complaint (January 2019) describes him as a Purdue vice president by 2001 as well as a director. - In a sworn July 2019 declaration in the Massachusetts case, he stated that he served on the board of Purdue Pharma Inc. "until January 16, 2019," that he lives in New York, and that he attended university in Massachusetts from 1989 to 1993. - Internal documents reviewed by The Examination and The Washington Post (2024) list him as a director of four European [[Mundipharma]] companies in 2013. In a November 2013 email he called a German five-year sales plan "totally unacceptable" and asked, "Why the conservatism?" (one source: a single joint investigation). ## What the money trail showed In September 2019 the New York attorney general's office filed bank records it had obtained by subpoena. As reported by AP and CNN, the records showed: | Item | Amount | Detail | |---|---|---| | Wire transfers involving him | ~$20 million (137 transfers) | Some as recent as 2018 | | Payment from "Purdue Pharma Trust MDAS" | $64 million | Routed through a Swiss bank account | | Central Eight Realty LLC | ~$40 million | Shell company holding a Manhattan townhouse | | Cherry Tree Holdings LLC | ~$4 million | Shell company holding an Amagansett home | Prosecutors said the shell companies' ownership "would have been impossible to detect from publicly available records." The Massachusetts complaint's allegations against the eight Sackler directors are mostly collective: board control of Purdue, and the billions the family paid itself. He did not testify at the December 2020 [[House Oversight Committee]] hearing; the family's witnesses were [[Kathe Sackler]] and [[David Sackler]]. ## Settlement After [[Harrington v. Purdue Pharma]] (June 27, 2024) struck down the non-consensual release in the first plan, the January 2025 framework named "Mortimer Jr." among the eight heirs. Accounts of the Sackler contribution differ: "up to $6.5 billion" over 15 years (Tennessee AG), or up to $7 billion (AP/PBS). The sources reviewed do not break down individual shares. Judge Sean Lane ruled from the bench on November 14, 2025, and entered the confirmation order on November 18, 2025. The plan took effect on May 1, 2026. Purdue's operating assets passed to Knoa Pharma, and the family made a $1.5 billion payment on the effective date. The release protects him only against claimants who opted in; claimants who did not opt in can still sue. ## See Also - [[Sackler Family]] · [[Mortimer Sackler]] · [[Theresa Sackler]] · [[Kathe Sackler]] · [[Ilene Sackler Lefcourt]] - [[Purdue Pharma]] · [[Mundipharma]] · [[OxyContin]] · [[Harrington v. Purdue Pharma]] · [[Opioid Crisis Timeline]]